June 5, 2026
ExoMira’s recent engagements from AACR to ASCO have strengthened the company’s strategic positioning of MIRA-1 as a potential world-first immune-converting Treg-IO therapy with direct cancer-killing activity.

March 4, 2026
ExoMira’s recent key discoveries include: (1) USP22 inhibits neoantigen presentation; (2) increased USP22 is associated with ICB therapeutic resistance; (3) USP22i overcomes the ICB resistance in lung and TNBC treatment.

February 19, 2026

An ExoMira founder-authored study demonstrating that a natural product can inhibit USP22 and boost antitumor immunity strengthens our conviction that MIRA-1 could deliver differentiated—and potentially safer—cancer immunotherapy.

October 6, 2025

ExoMira celebrates the 2025 Nobel Prize for Treg discovery as it advances its first-in-class USP22 inhibitor, a Treg-targeted cancer immunotherapy built on this landmark biology.

September 17, 2025

ExoMira team members received AACR’s Top Poster Award for applying deep learning to characterize immune tumor ecosystems for prognostic cancer assessment.

June 4, 2025

Drs. Fang and Liu were awarded a Lurie Cancer Center Research Innovation Challenge Award to advance USP22 inhibitor development toward clinical trial readiness.